Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Targeted potassium levels to decrease arrhythmia burden in high risk patients with cardiovascular diseases (POTCAST): Study protocol for a randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Atrial fibrillation burden and cognitive decline in elderly patients undergoing continuous monitoring

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Nationwide cardiovascular disease admission rates during a second COVID-19 lockdown

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Genotype-phenotype correlation in arrhythmogenic right ventricular cardiomyopathy-risk of arrhythmias and heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. SARS-CoV-2 Surface Swabs in Locations With Public Access-Potential for Improved Source Control

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Low plasma potassium (p-K) is associated with increased risk of malignant arrhythmia and observational studies indicate protective effects of p-K in the upper reference level. However, randomized clinical studies are needed to document whether actively increasing p-K to high-normal levels is possible and safe and improves cardiovascular outcomes.

OBJECTIVE: To investigate if increased p-K reduces the risk of malignant arrhythmia and all-cause death in high-risk patients with a cardiovascular disease treated with an implantable cardioverter defibrillator (ICD) for primary or secondary preventive causes. Secondly, to investigate whether high-normal p-K levels can be safely reached and maintained using already available medications and potassium-rich dietary guidance.

METHODS: This is a prospective, randomized, and open-labelled study enrolling patient at high-risk of malignant arrhythmias. According to sample size calculations, 1,000 patients will be randomized 1:1 to either an investigational regiment that aims to increase and maintain p-K at high-normal levels (4.5-5.0 mmol/l) or to usual standard of care and followed for an expected four years. The trial will run until a total of 291 events have occurred providing an α=0.05 and 1-β=0.80. The composite primary endpoint includes ventricular tachycardia >125 bpm lasting >30 seconds, any appropriate ICD-therapy, and all-cause mortality. At present, 739 patients have been randomized.

CONCLUSIONS: We present the rationale for the design of the POTCAST trial. The inclusion was initiated 2019 and is expected to be finished 2022. The study will show if easily available treatments to increase p-K may be a new treatment modality to protect against malignant arrythmias.

OriginalsprogEngelsk
TidsskriftAmerican Heart Journal
Vol/bind253
Sider (fra-til)59-66
Antal sider8
ISSN0002-8703
DOI
StatusE-pub ahead of print - 11 jul. 2022

Bibliografisk note

Copyright © 2022. Published by Elsevier Inc.

ID: 79406733